These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23577259)

  • 1. Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer.
    Pisano C; Cecere SC; Di Napoli M; Cavaliere C; Tambaro R; Facchini G; Scaffa C; Losito S; Pizzolorusso A; Pignata S
    J Drug Deliv; 2013; 2013():898146. PubMed ID: 23577259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
    Rakowski JA; Ahmad S; Holloway RW
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin in the management of ovarian cancer.
    Ferrandina G; Corrado G; Licameli A; Lorusso D; Fuoco G; Pisconti S; Scambia G
    Ther Clin Risk Manag; 2010 Oct; 6():463-83. PubMed ID: 20957139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
    Markman M
    Cancer Manag Res; 2011; 3():219-25. PubMed ID: 21792330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
    Grenader T; Rosengarten O; Isacson R; Plotkin Y; Gabizon A
    World J Clin Oncol; 2012 Oct; 3(10):137-41. PubMed ID: 23198277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
    Nowak-Markwitz E
    Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
    Blake EA; Bradley CA; Mostofizadeh S; Muggia FM; Garcia AA; Roman LD; Matsuo K
    Arch Gynecol Obstet; 2019 Jun; 299(6):1641-1649. PubMed ID: 30824986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
    Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
    Pignata S; Lauraine EP; du Bois A; Pisano C
    Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
    Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
    Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in ovarian cancer.
    Strother R; Matei D
    Ther Clin Risk Manag; 2009 Jun; 5(3):639-50. PubMed ID: 19707541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
    Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
    Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
    Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
    Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
    Villanucci A; Tavella K; Vannini L; Rossi V; Nobili S; Amunni G; Mazzei T; Mini E
    Mol Clin Oncol; 2018 Dec; 9(6):635-639. PubMed ID: 30546893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
    Gordon AN; Fleagle JT; Guthrie D; Parkin DE; Gore ME; Lacave AJ
    J Clin Oncol; 2001 Jul; 19(14):3312-22. PubMed ID: 11454878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.
    Lorusso D; Ferrandina G; Lo Voi R; Fagotti A; Scambia G
    J Chemother; 2004 Nov; 16 Suppl 4():98-103. PubMed ID: 15688622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
    Kubeček O; Bláha M; Diaz-Garcia D; Filip S
    Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.